Bellerophon Therapeutics LLC Stock Nasdaq
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
05-02 | North American Morning Briefing : Stock Futures -2- | DJ |
04-25 | North American Morning Briefing : More Tech -2- | DJ |
Sales 2021 | - | Sales 2022 | - | Capitalization | 8.59M 0 11.74M |
---|---|---|---|---|---|
Net income 2021 | -17M - -23.24M | Net income 2022 | -19M - -25.97M | EV / Sales 2021 | - |
Net cash position 2021 | 23.78M 0 32.51M | Net cash position 2022 | 6.72M 0 9.19M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.66
x | P/E ratio 2022 |
-0.43
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 84.97% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Jalbert
CEO | Chief Executive Officer | 63 | - |
Martin Dekker
CTO | Chief Tech/Sci/R&D Officer | 51 | 15-01-28 |
Edwin L. Parsley
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Naseem Amin
CHM | Chairman | 62 | 15-06-28 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |